Login to Your Account



Other News To Note


Tuesday, April 5, 2011
Plexxikon Inc., of Berkeley, Calif., said its acquisition by Daiichi Sankyo Co. Ltd., of Tokyo, was completed. Under the terms of the deal, Plexxikon shareholders will receive $805 million up front, with near-term milestones associated with approval of melanoma drug PLX4032 totaling an additional $130 million.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription